American Oncology Network Announces Leaders Participating in ACCC’s Annual Meeting & Cancer Center Business Summit
Alti Rahman and Susan Sabo-Wagner were selected as panelists at the Association of Cancer Care Centers event in Washington, D.C....
Month: March 2024
Clene to Present at the 36th Annual ROTH Conference
SALT LAKE CITY, March 07, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its...
Reviva to Present at the 36th Annual ROTH Conference
CUPERTINO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage...
Strainsforpains, Inc. Investors Update: Strainsforpains, Inc. Showing Strong Revenue Growth
NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- -- (E-Buy Homes, Inc. DBA/Strainsforpains, Inc.) (OTC Markets: EBYH) Strainsforpains, Inc. is...
SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe
The Company's most recent patent further solidifies its position, complementing existing grants in the U.S., Japan, Australia and other key...
Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma
MB-101 was well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses...
MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report
NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery,...
Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results
Q4 Net Revenues up 88% to $26.3 million vs. Q4 20222023 Net Revenues up 49% to $80.8 million vs. 2022Increases...
Arch Biopartners Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
TORONTO, March 07, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF),...
Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
PDUFA target action date is March 16, 2024, for the Company's sNDA. If approved, the Company is prepared for launch...
Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024
STAMFORD, Conn., March 07, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment...
Helius Medical Technologies, Inc. to Present at the 36th Annual ROTH Conference
NEWTOWN, Pa., March 07, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company...
Manitoba Harvest Hemp Foods Introduces Protein-Rich Breakfast Staples With New Superseed Instant Oatmeal
Global Hemp Food Leader, Manitoba Harvest, Launches New Superseed Instant Oatmeal in Three Delicious Flavors Packed with Plant-Based Protein, Fiber,...
Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook
• Dose escalation in FHD-286 combination study in AML continues to progress; clinical data anticipated in the second half of...
EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments
– Announced positive topline efficacy and safety data from the Phase 2 DAVIO 2 trial of EYP-1901 in wet AMD...
Harvard Bioscience Announces Fourth Quarter 2023 Financial Results
Q4 Revenues of $28.2 millionQ4 Gross Margin of 58.0% (230 bps year-over-year improvement)Q4 operating income of $0.3 million, adjusted operating...
Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
On-track to report topline Phase 3 data from the KOASTAL-1 study with navacaprant in MDD in the second half of...
Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
Topline data from Phase 2b study of Descartes-08, the Company’s potential first-in-class mRNA CAR-T cell therapy, in myasthenia gravis (MG)...
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
– Additional monotherapy dose-escalation data from ongoing Phase 1/1b clinical trial of WTX-124 expected to be presented in the first...
Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHD
CHARLESTOWN, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic...